Er WuXi AppTec Co udbyttet sikkert?
WuXi AppTec Co har øget udbyttet i 3 år.
Inden for de seneste 9 år har WuXi AppTec Co øget denne med 0 % årligt sænket.
På 5-årssigt faldt udbetalingen med 0 %.
Analytikerne forventer en Dividendeøgning på 7,478% for det igangværende regnskabsår.
WuXi AppTec Co Aktienanalyse
Hvad laver WuXi AppTec Co?
WuXi AppTec Co Ltd is a Chinese company that was founded in 2000 and specializes in the development of customer-oriented services in the pharmaceutical research and in vitro diagnostics sectors. The company operates multiple facilities in China, the USA, Europe, and Singapore.
The business model of WuXi AppTec is based on the development and provision of services to meet the needs of customers worldwide. This includes activities such as bioanalysis, chemical development, drug manufacturing, and regulatory compliance and quality assurance services.
In terms of various industries, the company is divided into three main divisions.
The Chemical Division specializes in chemical development and drug manufacturing. The team has expertise in synthesizing complex molecules, scaling up for clinical trials, manufacturing bulk products for commercial use, and supplying APIs for formulation. The company has state-of-the-art facilities and technologies to ensure high product quality and fast production time.
The Medical Device Division provides in vitro diagnostics for the global market to enable rapid and reliable medical diagnosis. The focus is on developing innovative technologies and applications in the fields of oncology, infectious diseases, and neurology. The company has many partnerships with leading in vitro diagnostics companies to enhance the quality and reach of products and services.
The Biological Division specializes in the development of biopharmaceutical products and services. This includes the development of monoclonal antibodies to the production of recombinant proteins. The services include process development, manufacturing, characterization, and analysis of biological products. WuXi AppTec is at the forefront of technology and provides its customers with state-of-the-art facilities and technologies.
In addition to the aforementioned services, WuXi AppTec also offers solutions in the field of bioanalytics, supporting the development of analytical methods and drug validation.
The company has also recently expanded into other areas, including the acquisition of NextCODE Health, a firm specializing in genetic diagnostics and analysis tools.
The company operates internationally and collaborates with a wide range of customers in the pharmaceutical and biotech sectors. It is also part of a global network of companies focusing on therapeutic technologies, clinical trials, drug marketing, and other aspects of the pharmaceutical industry.
WuXi AppTec aims to provide its customers with high-quality products and services that are scientifically sound and effective. The company invests in research and development to provide its customers with the latest technologies and discoveries. WuXi AppTec Co er et af de mest populære virksomheder på Eulerpool.com.Aktiespareplaner tilbyder en attraktiv mulighed for investorer at opbygge formue på lang sigt. En af de største fordele er den såkaldte cost-average-effekt: Ved regelmæssigt at investere et fast beløb i aktier eller aktiefonde, køber man automatisk flere andele, når priserne er lave, og færre, når de er høje. Dette kan føre til en mere fordelagtig gennemsnitspris per andel over tid. Desuden giver aktiespareplaner også småinvestorer adgang til dyre aktier, da de kan deltage med små beløb. Den regelmæssige investering fremmer også en disciplineret investeringsstrategi og hjælper med at undgå følelsesladede beslutninger, som impulsiv køb eller salg. Derudover drager investorer fordel af den potentielle værdistigning af aktierne samt af udbytteudlodninger, der kan geninvesteres, hvilket forstærker renters rente effekten og dermed væksten af det investerede kapital.